The company said, “We will continue to focus and maintain our strict cost control and diligently prioritize and optimize our resource allocation. This enables us to absorb the general cost increase, inflation and increased level of activity in 2025 within the same cash spend as in 2024, e.g. we expect an operational cash burn of approximately $14 million in 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion A/S to Announce Q1 2025 Financial Results and Business Update
- Evaxion Begins Extension of Phase 2 Trial for AI-Designed Cancer Vaccine
- Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01
- Evaxion Biotech A/S Announces Key Resolutions from April 2025 AGM
- Evaxion Biotech Updates Warrant Terms and Subscription Prices